Form 4 for GANX Gain Therapeutics, Inc.
Accepted 2023-12-14 00:00:00 ET · period of report 2023-12-07 · accession 0001104659-23-126020 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-12-14 | 2023-12-07 | GANX | Alder Matthias | CEO, Dir | S - Sale | $2.50 | -1,820 | 4,855 | -27% | -$4,550 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-07 | S | D | 1,820 | $2.50 | 4,855 | D | — | — | (F1) Reflects shares sold to cover withholding taxes incurred upon the vesting and settlement of restricted stock units in a trade that was initiated by the Issuer on the Reporting Person's behalf. (F2) The price reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.48 to $2.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range specified in this footnote. |